MichaelJohnMauroMD

PubMed

• 54 citations
  Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial.
  Tim H Brümmendorf, Jorge E Cortes, Dragana Milojkovic, Carlo Gambacorti-Passerini, Richard E Clark
  Leukemia. 2022-07-01
• 54 citations
  BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase
  Timothy P. Hughes, Giuseppe Saglio, Alfonso Quintás-Cardama, Michael J. Mauro, Dong-Kee Kim
  Leukemia. 2015-09-01
• 126 citations
  A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs
  Delphine Rea, Michael J. Mauro, Carla Boquimpani, Yosuke Minami, Elza Lomaia
  Blood. 2021-11-25

Abstracts/Posters

• Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia
  Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cardiovascular (CV)-Related Hospitalizations and Associated Costs Among US Patients in Simplicity: An Observational Study of Patients with Chronic-Phase Chronic Myeloi...
  Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Safety and Efficacy of Combined Ruxolitinib and Thalidomide in Patients with Myelofibrosis: A Phase II Study
  Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Cytogenetic and Molecular Response with First- and Second-Generation Tyrosine Kinase Inhibitor (TKI) Therapy in Simplicity: An Observational Study of Patients with Chr...
  Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
• Phase 1 Trial of K0706, a Novel Oral BCR-ABL1 Tyrosine Kinase Inhibitor (TKI): In Patients with Chronic Myelogenous Leukemia (CML) and Phildelphia Positive Acute Lymph...
  Michael J. Mauro, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
• Join now to see all

Lectures

• A multicenter, randomized phase III study of asciminib (ABL001) versus bosutinib in patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP) previously t... 
  2019 ASCO Annual Meeting - 6/1/2019
• Dosing Patterns of Dasatinib Use in Simplicity, an Observational Study in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients (pts) in Routine Clinical Practice 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Cardiovascular Mortality Among CML Patients in the Pre-TKI and TKI Eras: A SEER Analysis 1992-2004 
  2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
• Clinical development of asciminib (ABL001) in chronic myeloid leukemia (CML): A randomized phase 3 study vs. bosutinib. 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
• 2012 Highlights of ASH in North America (San Francisco, CA) 
  American Society of Hematology (ASH), San Francisco, California - 2/3/2012
• Join now to see all